Abstract
Epigenetic alterations have been identified as promising new targets for cancer prevention strategies as they occur early during carcinogenesis. Therapy is mainly focused on reversion of DNA methylation by inhibiting DNA-methyltransferases and low level of acetylated histones by inhibiting histone deacetylases. DIM and epigallocatechin-3-gallate (EGCG) substances are believed to be an anticancer agent in part through its regulation of epigenetic processes. These agents demonstrate efficacy in cancer chemopreventive action and have potential to be used to current cancer therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
